Metabolism
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 25157 | ALT-007 | 2035010-37-6 | ≧98.0% |  |
| ALT-007 is an orally bioavailable SPT inhibitor that is more potent than myriocin, sa | ||||
| 193264 | PF-06835919 ( MDK-1846 ) | 2102501-84-6 | ≧98.0% |  |
| MDK1846 is a potent ketohexokinase (KHK) inhibitor. | ||||
| 20625 | Orismilast ( LEO-32731 ) | 1353546-86-7 | ≧98.0% |  |
| Orismilast is a phosphodiesterase type 4 (PDE4) inhibitor. | ||||
| 1812292 | UC-1728 | 948304-40-3 | ≧98.0% |  |
| UC-1728, also known as t-TUCB, is a Soluble epoxide hydrolase inhibitor. | ||||
| 218701 | TOVINONTRINE ( IMR-687 ) | 2062661-53-2 | ≧98.0% | _2062661-53-2.gif) |
| TOVINONTRINE ( IMR-687 ) is a highly selective and potent small molecule inhibitor of | ||||
| 111895 | Oteseconazole | 1340593-59-0 | ≧98.0% |  |
| Oteseconazole, also known as VT-1161,is the first Approved Orally Bioavailable and Se | ||||
| 512193 | ITI-214(phosphate) | 1642303-38-5 | 98% Min. |  |
| ITI-214 is a potent and selective phosphodiesterase 1 (PDE1) inhibitor. As the clinic | ||||
| 822221 | IACS-13909 | 2160546-07-4 | ≧98.0% |  |
| IACS-13909 is a specific and potent allosteric inhibitor of SHP2, that suppresses sig | ||||
| 20511 | PDD4091 | 1373651-41-2 | ≧98.0% |  |
| PDD4091 is a novel G6PD inhibitor. | ||||
| 20594 | JTE-151 | 1404380-58-0 | ≧98.0% |  |
| JTE-151 is a novel RORγ inverse agonist. | ||||
| 20642 | OATD-02 | 2146132-73-0 | ≧98.0% |  |
| OATD-02, an orally available dual arginase inhibitor (ARG1 and ARG2), is in phase I c | ||||
| 24009 | Asengeprast (FT011) | 1001288-58-9 | ≧98.0% |  |
| Asengeprast (FT011) is an anti-fibrotic agent thatreduces mRNA expression of collagen | ||||